Education
About Us
Working with TipRanks
Follow Us
Vivos Therapeutics (VVOS)
NASDAQ:VVOS
Total Valuation
Vivos Therapeutics has a market cap or net worth of $17.96M. The enterprise value is $8.14M.
Market Cap$17.96M
Enterprise Value$8.14M
Share Statistics
Vivos Therapeutics has 5,889,520 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,889,520
Owned by Insiders1.24%
Owned by Institutions5.13%
Financial Efficiency
Vivos Therapeutics’s return on equity (ROE) is -1.40 and return on invested capital (ROIC) is -99.21%.
Return on Equity (ROE)-1.40
Return on Assets (ROA)-0.73
Return on Invested Capital (ROIC)-99.21%
Return on Capital Employed (ROCE)-1.08
Revenue Per Employee137.90K
Profits Per Employee-102.17K
Employee Count109
Asset Turnover0.98
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Vivos Therapeutics is -1.93. Vivos Therapeutics’s PEG ratio is -0.13.
PE Ratio-1.93
PS Ratio0.00
PB Ratio1.93
Price to Fair Value2.71
Price to FCF-0.45
Price to Operating Cash Flow-0.47
PEG Ratio-0.13
Income Statement
In the last 12 months, Vivos Therapeutics had revenue of 15.03M and earned -11.14M in profits. Earnings per share was -1.68.
Revenue15.03M
Gross Profit9.02M
Operating Income-11.17M
Pretax Income-11.14M
Net Income-11.14M
EBITDA-10.55M
Earnings Per Share (EPS)-1.68
Cash Flow
In the last 12 months, operating cash flow was -13.97M and capital expenditures -14.00K, giving a free cash flow of -13.98M billion.
Operating Cash Flow-13.97M
Free Cash Flow-13.98M
Free Cash Flow per Share-2.37
Dividends & Yields
Vivos Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.65
52-Week Price Change51.80%
50-Day Moving Average2.51
200-Day Moving Average3.24
Relative Strength Index (RSI)74.63
Average Volume (3m)166.76K
Important Dates
Vivos Therapeutics upcoming earnings date is Aug 13, 2025, After Close (Confirmed).
Last Earnings DateMay 15, 2025
Next Earnings DateAug 13, 2025
Ex-Dividend Date―
Financial Position
Vivos Therapeutics as a current ratio of 1.50, with Debt / Equity ratio of 50.26%
Current Ratio1.50
Quick Ratio1.50
Debt to Market Cap0.02
Net Debt to EBITDA0.45
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Vivos Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Vivos Therapeutics EV to EBITDA ratio is -1.59, with an EV/FCF ratio of -1.27.
EV to Sales1.12
EV to EBITDA-1.59
EV to Free Cash Flow-1.27
EV to Operating Cash Flow-1.32
Balance Sheet
Vivos Therapeutics has $2.34M in cash and marketable securities with $1.40M in debt, giving a net cash position of -$943.00K billion.
Cash & Marketable Securities$2.34M
Total Debt$1.40M
Net Cash-$943.00K
Net Cash Per Share-$0.16
Tangible Book Value Per Share$0.94
Margins
Gross margin is 62.52%, with operating margin of -74.32%, and net profit margin of -74.09%.
Gross Margin62.52%
Operating Margin-74.32%
Pretax Margin-74.09%
Net Profit Margin-74.09%
EBITDA Margin-70.22%
EBIT Margin-74.32%
Analyst Forecast
The average price target for Vivos Therapeutics is $4.23, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.23
Price Target Upside25.52% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast9.47%
EPS Growth Forecast81.37%